Treatment of Schambergs disease with pentoxifylline - therapeutic trial

Thirty patients with Schamberg s disease were started on pentoxifylline (400 mg three times daily) for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two observers independently and graded as mild ( 25%), moderate (25-50%) and marked ( 50%). Marked improvement was observed in 15/30 (50%) patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg s disease.